EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Long–Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine

Soohyun Cho, Byung-Kun Kim

Current Pain and Headache Reports · 2024-08 · 28 (8) · 743-751

DOI: 10.1007/s11916-024-01259-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Pain and Headache Reports, online erschienen am 29.04.2024. Verfasst von Soohyun Cho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: Calcitonin gene-related peptide (CGRP)-targeting agents are potential candidates for disease-modifying migraine drugs. However, most studies on CGRP-targeting agents have assessed efficacy outcomes rather than long-term effects after discontinuation. This review aimed to synthesize and scrutinize the latest clinical data on the outcomes after the discontinuation of CGRP-targeting therapy in patients with episodic and chronic migraine, with a particular focus on chronic migraine. RECENT FINDINGS: Real-world studies involving patients with migraine have reported consistent findings of worsened headache frequency and quality of life after the discontinuation of CGRP monoclonal antibodies (CGRP mAbs). Although many patients maintain improvements for up to 4 months after discontinuation compared to baseline (before starting CGRP mAbs), no studies have evaluated the effects of stopping treatment for > 5 months, which is the five-half-life of CGRP mAbs. Several studies have suggested that patients treated with CGRP receptor mAbs experience more rapid deterioration than those treated with CGRP ligand mAbs after discontinuing CGRP mAbs. The results of real-world studies suggest that for many patients with migraine, the benefits of CGRP mAbs diminish months after discontinuation. Therefore, anti-CGRP therapies may not be considered disease-modifying. However, the comprehensive assessment of the disease-modifying potential of these drugs requires studies with extended treatment and cessation durations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related PeptideHumansCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, MonoclonalTreatment Outcome

Stichwörter der Autor:innen

CGRP-targeting therapyCalcitonin gene-related peptide monoclonal antibodies (CGRP mAbs)Chronic migraineDiscontinuationDisease-modifying migraine drug (DMMD)

Substanzen

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea.
  • Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea. kbk1403@eulji.ac.kr.

Zitieren

APA

Cho, S., & Kim, B. K. (2024). Long–Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine. Current Pain and Headache Reports, 28(8), 743-751. https://doi.org/10.1007/s11916-024-01259-x

Vancouver

Cho S, Kim BK. Long–Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine. Current Pain and Headache Reports. 2024;28(8):743-751. doi:10.1007/s11916-024-01259-x

BibTeX
@article{Cho2024,
  author = {Cho, Soohyun and Kim, Byung-Kun},
  title = {Long–Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine},
  journal = {Current Pain and Headache Reports},
  year = {2024},
  volume = {28},
  number = {8},
  pages = {743--751},
  doi = {10.1007/s11916-024-01259-x}
}
Kostenlos starten →